Skin Disposition Study Results

TULLE, France, September 14, 2015 (Newswire.com) - a specialty biopharmaceutical company centered on delivery innovative and differentiated merchandise to dermatologists and their patients, these days declared the presentation of recent knowledge for DRM01, a novel, topical secretion substance in development for the treatment of inflammatory disease. The results from a study in geographic region pigs incontestible that DRM01 penetrates the skin during a dose- and formulation-dependent manner and accumulates within the oily glands. These animals have skin morphology and physiology almost like human skin, together with well-developed oily glands, suggesting that the compound could effectively localize at the positioning of accumulated secretion production within the skin of patients with inflammatory disease. These results were conferred these days at the forty fifth Annual Meeting of the ecu Society for dermatologic analysis (ESDR) in urban center, European country. Dermira's DRM01 is presently being investigated during a dose-finding section 2b run as a topical treatment in patients with facial acne, and topline results from this trial ar expected within the half of 2016 supported current enrollment projections.​